American University of Beirut Medical Center, PO Box 11-0236/11D, Riad El Solh 1107 2020, Beirut, Lebanon.
Future Microbiol. 2011 Jan;6(1):9-18. doi: 10.2217/fmb.10.132.
Several studies have shown that the rates of resistant Gram-positive pathogens, such as methicillin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus (VISA), hetero-VISA, and penicillin-resistant Streptococcus pneumoniae have witnessed a substantial global increase. Ceftaroline fosamil is the prodrug form of ceftaroline, a new cephalosporin active against resistant Gram-positive pathogens and common Gram-negative organisms that do not produce extended-spectrum-β-lactamases and do not express AmpC. Ceftaroline fosamil was found to be effective and well-tolerated for the treatment of complicated skin and skin-structure infections and community-acquired bacterial pneumonia compared with standard therapy. The drug has recently been granted US FDA approval for both indications.
多项研究表明，耐甲氧西林金黄色葡萄球菌、万古霉素中介金黄色葡萄球菌（VISA）、异质性万古霉素中介金黄色葡萄球菌（hVISA）和青霉素耐药肺炎链球菌等耐药革兰阳性病原体的发生率在全球范围内显著增加。头孢洛林酯是头孢洛林的前体药物，头孢洛林是一种新型头孢菌素，对耐药革兰阳性病原体和常见革兰阴性菌均具有活性，这些细菌不产生超广谱β-内酰胺酶，也不表达 AmpC。与标准疗法相比，头孢洛林酯治疗复杂皮肤和皮肤结构感染以及社区获得性细菌性肺炎的疗效和安全性良好。该药物最近已获得美国 FDA 批准用于这两种适应证。
